Aligos Therapeutics, Inc. Stock Price, News & Analysis

Aligos Therapeutics (Nasdaq: ALGS) announced significant advancements in its drug development pipeline for NASH, COVID-19, and CHB diseases, highlighting progress in clinical trials and positive data from candidate ALG-055009. The company reported a cash balance of $125.8 million as of December 31, 2022, down from $205.8 million in 2021, but sufficient to fund operations through the end of 2024. Net losses decreased to $21.9 million for Q4 2022, compared to $37.7 million in Q4 2021, and annual losses were $96.0 million, down from $128.3 million.

The firm anticipates key data readouts throughout 2023, which could drive shareholder value.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced it will report its fourth quarter 2022 financial results on March 9, 2023, after U.S. market close. The company specializes in developing therapeutics targeting nonalcoholic steatohepatitis (NASH) and viral diseases, aiming to be a leader in liver disease treatment. Founded in 2018, Aligos is focusing on advancing its pipeline of potentially best-in-class molecules. The press release includes forward-looking statements, highlighting risks such as drug development uncertainties and capital resource sufficiency.

Aligos Therapeutics (Nasdaq: ALGS) delivers multiple presentations at the 32nd APASL Conference in Taipei from Feb 15-19, 2023. The focus is on ALG-055009, a THR-β agonist for NASH, and various compounds in its chronic hepatitis B (CHB) portfolio. Promising data for ALG-055009 indicates positive anti-lipid effects in hyperlipidemic subjects. Additionally, significant antiviral activity is noted for ALG-000184, achieving notable reductions in HBsAg levels with higher doses. The presentations demonstrate Aligos' commitment to advancing treatments for liver diseases and viral infections.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) will present key data at the 32^nd Conference of the Asian Pacific Association for the Study of the Liver (APASL) from February 15-19, 2023, in Taipei, Taiwan. The company will focus on its THR-β agonist, ALG-055009, targeting nonalcoholic steatohepatitis (NASH), with a Phase 2 filing anticipated by year-end. Additionally, insights into its chronic hepatitis B (CHB) portfolio will be showcased. Notable presentations include results on the capsid assembly modulator ALG-000184, highlighting significant reductions in HBsAg levels in patients.

On February 10, 2023, Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that its CEO, Lawrence M. Blatt, Ph.D., MBA, will present at the SVB Securities Global Biopharma Conference on February 15, 2023, from 5:00 to 5:30 p.m. ET. The conference will be virtual, and a replay of the presentation will be available for 90 days on Aligos' investor website. Aligos is focused on developing therapeutics for nonalcoholic steatohepatitis (NASH) and viral diseases, utilizing its expertise in clinical drug development. The company aims to be a leader in addressing unmet medical needs in these areas.

Aligos Therapeutics (Nasdaq: ALGS) has announced a portfolio reprioritization focusing on its NASH and COVID-19 programs, particularly ALG-055009 and ALG-097558. The company is reducing its workforce by approximately 10% and has seen a total reduction of 25% since January 2022. This strategic shift aims to maintain a strong balance sheet and extend its cash runway until late 2024. Aligos plans to complete clinical studies for its NASH and chronic hepatitis B programs and collaborate with Merck on NASH research. Financial results for Q4 and year-end 2022 will be reported in mid-March 2023.

Aligos Therapeutics (Nasdaq: ALGS) is on track to complete Phase 2-enabling activities for its thyroid hormone receptor beta drug candidate, ALG-055009, for nonalcoholic steatohepatitis by 2023. Initial Phase 1 data shows favorable pharmacokinetics, indicating potentially more predictable dosing across patients compared to leading competitors. The final Phase 1 cohort is expected to finish in H1 2023, while toxicology studies are projected for completion in H2 2023. A comprehensive pipeline update will be discussed at the J.P. Morgan Healthcare Conference on January 12, 2023.

Aligos Therapeutics has initiated dosing of ALG-125755, a small interfering RNA targeting hepatitis B surface antigen (HBsAg), in chronic hepatitis B (CHB) patients as part of Study ALG-125755-501. This advancement follows successful evaluation in healthy volunteers. The company aims to explore various dosing regimens throughout 2023, potentially identifying a combination therapy regimen. Aligos plans to present study data at scientific conferences this year, highlighting their commitment to innovative treatments for viral and liver diseases.

Aligos Therapeutics (ALGS) announced promising progress in the development of its coronavirus protease inhibitor, ALG-097558, during the 2022 Respi DART meeting. The drug demonstrated significant in vivo antiviral activity and effective viral replication inhibition in human cell cultures. First-in-human trials are expected to commence in H1 2023. CEO Lawrence Blatt highlighted ALG-097558's superior potency against SARS-CoV-2, a favorable profile against mutations, and a predicted dosing regimen without the need for ritonavir boosting. The candidate is being developed with international collaboration.